Eos
Eos Advisory LLP is an FCA-regulated, St Andrews-based investment firm founded in 2014 that deploys seed and growth capital into UK science and technology companies via an Angel Syndicate, Innovation Fund and Venture Partners platform, serving family offices, HNW individuals and institutional investors alongside British Business Investments.
- Company typePrivate
- Founded2014
- HeadquartersSaint Andrews, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Eos does
Eos Advisory LLP is an FCA-regulated, St Andrews-based investment firm founded in 2014 that specialises in early-stage science and technology companies across the UK, deploying capital through a three-vehicle platform: a member-driven Angel Syndicate (minimum £5k per investment, accounting for c. 13% of investments per annum), an Eos-managed Innovation Fund (annual Q4 close, £25k minimum, typical £100k-£500k tickets, 5-8 deals per year across separate vintages) and Venture Partners (ad-hoc growth and Series A+ co-investments, £25k minimum, £100k-£1M+ per deal). The firm's portfolio, comprising more than twenty companies, is split between quality of life (disease diagnostics, prevention and treatment, food and water security) and environmental sustainability (clean energy, sustainable infrastructure, pollution), and includes Scottish university spinouts such as Dxcover (spectroscopic liquid biopsy with AI), Bioliberty (soft robotics rehabilitation, with US expansion funded by a March 2026 Series A) and Nami Surgical (ultrasonic scalpels for robotic-assisted surgery), as well as Bristol-based EnsiliTech and Scarlet Therapeutics.
Eos is FCA-authorised (reference 980583) and offers S/EIS UK tax relief on relevant investments, working in long-term partnerships with family offices, individuals, companies and institutional investors, most notably via a £10 million commitment from British Business Investments in June 2023. The firm's go-to-market is direct and relationship-driven, supported by a content-led website, an Angel Syndicate community that meets virtually monthly and in-person quarterly, and co-marketing partnerships with UKBAA, EISA and the British Business Bank. Investment Committee and partner composition includes founders, scientists, industry leaders and government advisors, including Managing Partner Andrew McNeill, Partner Chris Brinsmead, Director of Portfolio Anne Muir, Investment Director Rob Halliday, and Investment Committee members Rick Clark, Andrew Durkie and Ana Stewart.
Eos firmographics
Firmographics- Name
- Eos
- Legal name
- Eos Advisory LLP
- Website
- https://eos-advisory.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Eos Advisory LLP is an FCA-regulated, St Andrews-based investment firm founded in 2014 that deploys seed and growth capital into UK science and technology companies via an Angel Syndicate, Innovation Fund and Venture Partners platform, serving family offices, HNW individuals and institutional investors alongside British Business Investments.
- Ownership category
- akta.pro rank
Eos industry classification
Industry- Product category
- Venture Capital / Impact Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Open-End Investment Funds (52591), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Healthcare Access & Life Sciences Impact Funds (FSANAJAI)
- akta.pro secondary industries
- SDG / Thematic Sustainable Investment Funds (FSANAJAN), Multi-Asset ESG / Sustainable Allocation Strategies (FSAAAJAK), Sustainable/ESG Equity (Active) (FSAAAIAM)
Keywords
Where Eos is headquartered
LocationHeadquarters
- HQ city
- Saint Andrews
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Eos business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund management & investment returns: Eos Advisory generates revenue via managed and discretionary investment vehicles (Innovation Fund and Venture Partners) that deploy capital into early-stage science & technology companies. Returns derive from capital appreciation of equity investments held in portfolio companies, plus carried interest/management economics typical of an FCA-regulated investment manager.
- Angel Syndicate arrangement & co-investment services: Eos arranges and administers an Angel Syndicate where members make investment decisions and commit equity capital alongside Eos-managed funds, with Eos providing deal sourcing, structuring and ongoing portfolio support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Angel Syndicate — member-led, minimum £5,000 per investment |
| Other | Annual | Innovation Fund — Eos-managed seed investments, minimum £25,000 (typical £100k–£500k) |
| Other | Pay-as-you-go | Venture Partners — growth & Series A+, minimum £25,000 (typical £100k–£1M+ per deal) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Eos product offering
Product offeringCore offering
Eos Advisory LLP is an FCA-regulated impact investment firm that deploys patient early-stage capital into UK science and technology companies through three complementary vehicles: an Angel Syndicate (member-driven, £5k minimum per investment), an Innovation Fund (Eos-managed seed investments with annual Q4 close, £25k minimum, £100k–£500k typical, 5–8 investments per year), and a Venture Partners programme (growth / Series A+ co-investment, £25k minimum, £100k–£1M+ typical). The portfolio is concentrated in quality of life (disease diagnostics, prevention and treatment, food and water security) and environmental sustainability (clean energy, sustainable infrastructure, pollution).
Product overview
Eos Advisory LLP operates a multi-vehicle investment platform rather than a single unified product: its offering is split across three complementary funding models — the Angel Syndicate (member-driven seed investing), the Innovation Fund (Eos-managed seed-stage fund), and Venture Partners (growth / Series A+ co-investments) — which together deploy early-stage patient capital into science and technology companies focused on quality of life and environmental sustainability. This investment platform is delivered alongside an Eos portfolio of seed- and growth-stage investee companies (e.g., Bioliberty, Dxcover, Laverock Therapeutics, Naturbeads, Penhros Bio, Chemify, Nami Surgical, Neupulse, EnsiliTech, Scarlet Therapeutics, Carcinotech, Biotangents, CamGene Therapeutics, Concinnity Genetics, Cumulus Oncology, Enough, GM Flow, ILC Therapeutics, Novosound, Novel Technologies / Silbac, and Wobble Genomics), offering S/EIS UK tax relief for relevant investors when available and long-term partnerships with family offices, individuals, companies, and institutional investors.
Differentiator
Problem solved
Functional benefit
Products and services
- Angel Syndicate
Quantifiable outcome
- British Business Investments committed up to £10 million to support Eos's early-stage science & technology investment activity across the UK
- +1 more outcomes
Companies that use Eos
Customer profileSegments3 records
Ideal customer profiles2 records
Eos technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Eos partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- UKBAA (UK Business Angels Association)coreListed as a UKBAA member on the Eos Advisory homepage; partner logo linked to ukbaa.org.uk membership page.
- EISA (Enterprise Investment Scheme Association)coreListed as a partner on the Eos Advisory homepage; partner logo linked to eisa.org.uk. Eos offers S/EIS UK tax relief for relevant investors when available, indicating alignment with EISA's mission.
- British Business BankcorePartner logo displayed on the Eos Advisory homepage, linked to bbinv.co.uk; supports the wider UK SME investment ecosystem in which Eos operates.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Eos competitors and assessment
Company assessmentDirect peers
- Archangels: Archangels is Scotland's longest-running angel investment syndicate, investing early-stage capital into Scottish technology and life sciences companies. It is directly comparable to Eos as a fellow Scottish early-stage specialist and was a co-investor with Eos in the Bioliberty Series A.
- Mercia Asset Management: Mercia is a UK regional venture capital and asset manager running EIS funds and university-connected vehicles across the Midlands and North of England. It is directly comparable to Eos as a UK regional seed/growth specialist and co-invested via its managed Midlands Engine Investment Fund II in the Neupulse round alongside Eos.
- Cambridge Innovation Capital: CIC is a Cambridge-based venture investor specialising in deep-tech and life-sciences spinouts from the University of Cambridge. It is directly comparable to Eos as a UK knowledge-intensive science and technology specialist at seed-to-growth stage.
- Parkwalk Advisors: Parkwalk is a UK investment manager specialising in university spinout and technology transfer opportunities, with EIS-eligible funds. It is directly comparable to Eos in focus on knowledge-intensive UK spinouts and use of S/EIS structures for HNW investors.
- Maven Capital Partners: Maven is a UK fund manager operating regional venture and growth funds including the Investment Fund for Scotland. It is directly comparable to Eos as a UK regional investor with managed seed/growth funds and was a co-investor with Eos in the Nami Surgical round.
Broad incumbents
- IP Group: IP Group is a listed UK IP commercialisation group that partners with universities to build deep-tech companies from research. It is a broader incumbent in the same university-spinout deep-tech niche that Eos targets, with a wider portfolio and public-market capital base.
- Octopus Ventures: Octopus Ventures is one of the largest UK VCs, backing science-, health- and deep-tech companies from seed to growth via funds such as Octopus Titan VCT. It is a broader incumbent in the same UK deep-tech seed-to-growth space Eos serves.
- Albion Capital: Albion Capital is a London-based investment manager with VCT/EIS funds backing UK growth-stage and technology companies. Comparable as a broader incumbent offering S/EIS-eligible structures to HNW investors, similar to Eos's Innovation Fund and Angel Syndicate vehicles.
Regional players
- Scottish Enterprise: Scottish Enterprise is Scotland's national economic development agency providing equity co-investment and grant funding to Scottish startups, including co-investing in Nami Surgical with Eos. Comparable as a regional institutional investor in Scottish science and technology companies.
- Scottish National Investment Bank: Scottish National Investment Bank is Scotland's development investment bank providing patient capital into Scottish companies. Comparable as a regional institutional investor in Scottish growth-stage companies and led the Bioliberty Series A that Eos participated in.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Eos social profiles
Digital presenceEos compliance and trust
Trust signalCompliance3 records
Eos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eos leadership team
Management profileNumber of profiles
Profiles10 records
Eos subsidiaries and ownership
Company hierarchySubsidiaries20 records
Eos funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eos M&A and investment
M&A and investmentM&A
Investments35 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eos
What does Eos do?
Eos Advisory LLP is an FCA-regulated impact investment firm that deploys patient early-stage capital into UK science and technology companies through three complementary vehicles: an Angel Syndicate (member-driven, £5k minimum per investment), an Innovation Fund (Eos-managed seed investments with annual Q4 close, £25k minimum, £100k–£500k typical, 5–8 investments per year), and a Venture Partners programme (growth / Series A+ co-investment, £25k minimum, £100k–£1M+ typical). The portfolio is concentrated in quality of life (disease diagnostics, prevention and treatment, food and water security) and environmental sustainability (clean energy, sustainable infrastructure, pollution).
Is Eos a public or private company?
Eos is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eos founded?
Eos was founded in 2014. It employs 1 to 10 people.
Where is Eos based?
Eos is headquartered in Saint Andrews, United Kingdom, in the Europe region.
How does Eos make money?
Two revenue lines are on record. Fund management & investment returns are the primary driver. The others are angel Syndicate arrangement & co-investment services.
Who are Eos's main competitors?
Direct peers on record are Archangels, Mercia Asset Management, Cambridge Innovation Capital, Parkwalk Advisors and Maven Capital Partners. Broad incumbents are IP Group, Octopus Ventures and Albion Capital. Regional players are Scottish Enterprise and Scottish National Investment Bank.
Does Eos have an API?
No public API is recorded for Eos.
What industry is Eos in?
Eos's product category is Venture Capital / Impact Investment Management. Its primary akta.pro industry code is FSANAJAI, Healthcare Access & Life Sciences Impact Funds, with a secondary code of FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 523940 and its SIC code is 6282.